False-negative BRCA1/BRCA2 mutation could affect the management of a high-risk cancer patient and his/her family members and could result in a missed opportunity of targeted therapy (e.g. poly(ADP-ribose) polymerases inhibitors in breast and ovarian cancers12). The gene discussed is BRCA2; the disease is cancer.